section name header

Pronunciation

KAL-see-um ASS -e-tate

Classifications

Therapeutic Classification: mineral and electrolyte replacements/supplements

Indications

REMS


Action

  • Binds to dietary phosphate to form an insoluble calcium phosphate complex, which is excreted in the feces, resulting in decreased serum phosphorus concentrations.
Therapeutic effects:
  • Control of hyperphosphatemia in end-stage renal disease without promoting aluminum absorption.

Pharmacokinetics

Absorption: Absorption from the GI tract requires vitamin D; 30–40% bioavailability.

Distribution: Readily enters extracellular fluid. Crosses the placenta and enters breast milk.

Metabolism/Excretion: Excreted mostly in the feces; 20% eliminated by the kidneys.

Half-Life: Unknown.

Time/Action Profile

(effects on serum calcium)

ROUTEONSETPEAKDURATION
POunknownunknownunknown

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: arrhythmias, bradycardia

F and E: hypercalcemia

GI: constipation, nausea, vomiting

GU: calculi, hypercalciuria

Neuro: headache, tingling

Interactions

Drug-drug:

Drug-Food:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

PhosLo